Chimeric Antigen Receptor T Cells in the Treatment of Multiple Myeloma.
Hematol Oncol Clin North Am
; 38(2): 383-406, 2024 04.
Article
em En
| MEDLINE
| ID: mdl-38158242
ABSTRACT
Chimeric antigen receptor T cells (CARTs) represent another powerful way to leverage the immune system to fight malignancy. Indeed, in multiple myeloma, the high response rate and duration of response to B cell maturation antigen-targeted therapies in later lines of disease has led to 2 Food and Drug Administration (FDA) drug approvals and opened the door to the development of this drug class. This review aims to provide an update on the 2 FDA-approved products, summarize the data for the most promising next-generation multiple myeloma CARTs, and outline current challenges in the field and potential solutions.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Receptores de Antígenos Quiméricos
/
Mieloma Múltiplo
Limite:
Humans
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article